A Single Center, Randomized, Open-Label, Controlled Pilot Study to Demonstrate Efficacy and Safety of the Addition of Inhaled Liposomal Cyclosporine (L-CsA) Therapy versus Standard Therapy Alone in the Treatment of Bronchiolitis Obliterans Syndrome (BOS) Following Lung Transplantation

被引：2
|
作者：
Iacono, A. [1 ]
Terrin, M. [2 ]
Rajakopal, K. [3 ]
McGrain, J. [1 ]
Barr, E. [2 ]
Rinaldi, J. [1 ]
Patel, A. [1 ]
Timofte, I. [4 ]
Kim, J. [4 ]
Kon, Z. [3 ]
Sanchez, P. G. [3 ]
Pierson, R. [3 ]
Griffith, B. [3 ]
Pham, S. [3 ]
机构：
[1] Univ Maryland, Shock Trauma & Transplantat, Baltimore, MD 21201 USA
[2] Univ Maryland, Epidemiol, Baltimore, MD 21201 USA
[3] Univ Maryland, Cardiothorac Surg, Baltimore, MD 21201 USA
[4] Univ Maryland, Pulm Crit Care, Baltimore, MD 21201 USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2016年 / 35卷 / 04期
关键词：
D O I：
10.1016/j.healun.2016.01.120
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
97
引用
收藏
页码：S44 / S45
页数：2
相关论文
共 8 条
  • [1] Association Between FEV 1 Decline Rate and Mortality in Long-Term Follow-Up of a 21-Patient Pilot Clinical Trial of Inhaled Liposomal Cyclosporine Plus Standard-of-Care Versus Standard-of-Care Alone for Bronchiolitis Obliterans Syndrome After Lung Transplantation
    Iacono, Aldo
    Wijesinha, Marniker
    Voelp, Andreas
    Korotun, Maksim
    Terrin, Michael
    ANNALS OF TRANSPLANTATION, 2024, 29
  • [2] Efficacy and Safety of Miglitol- or Repaglinide-Based Combination Therapy with Alogliptin for Drug-Naive Patients with Type 2 Diabetes: An Open-Label, Single-Center, Parallel, Randomized Controlled Pilot Study
    Okajima, Fumitaka
    Sugihara, Hitoshi
    Emoto, Naoya
    JOURNAL OF NIPPON MEDICAL SCHOOL, 2021, 88 (01) : 71 - 79
  • [3] Study Design of Two Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trials Evaluating the Efficacy and Safety of Liposomal Cyclosporin A for Inhalation(L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome Post Single- (BOSTON-1) or Double- (BOSTON-2) Lung Transplantation
    Fernandes, S. Prante
    Torres, V. Monforte
    Cuomo, D.
    Hachem, R. R.
    Boerner, G.
    McGrain, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [4] Efficacy and safety of oral therapy with iptacopan compared to standard intravenous therapy with eculizumab or ravulizumab in the treatment of paroxysmal nocturnal hemoglobinuria (PNH): results of the randomized controlled open-label multicenter phase III study APPLY-PNH
    Roeth, A.
    de Latour, R. Peffault
    Kulasekararaj, A.
    Scheinberg, P.
    Ueda, Y.
    de Castro, C.
    Di Bona, E.
    Schrezenmeier, H.
    Langemeijer, S. M.
    Barcellini, W.
    Panse, J.
    Schafhausen, P.
    Mauad, V. A.
    Kerloeguen, C.
    Kumar, R.
    Thorburn, C.
    Maitra, S.
    Dahlke, M.
    Risitano, A. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 42 - 44
  • [5] Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapy–controlled, phase 2 multicenter study (ONE-BRIDGE)
    Kazuya Ichikado
    Toru Kotani
    Yasuhiro Kondoh
    Hideaki Imanaka
    Takeshi Johkoh
    Kiminori Fujimoto
    Shin Nunomiya
    Tomotaka Kawayama
    Masanori Sawada
    Eric Jenkins
    Sadatomo Tasaka
    Satoru Hashimoto
    Stem Cell Research & Therapy, 14
  • [6] Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapy-controlled, phase 2 multicenter study (ONE-BRIDGE)
    Ichikado, Kazuya
    Kotani, Toru
    Kondoh, Yasuhiro
    Imanaka, Hideaki
    Johkoh, Takeshi
    Fujimoto, Kiminori
    Nunomiya, Shin
    Kawayama, Tomotaka
    Sawada, Masanori
    Jenkins, Eric
    Tasaka, Sadatomo
    Hashimoto, Satoru
    STEM CELL RESEARCH & THERAPY, 2023, 14 (01)
  • [7] Preliminary results of a randomized controlled, open-label, multi-center phase II study of camrelizumab combined with chemotherapy followed by concurrent chemoradiotherapy and camrelizumab consolidation therapy versus standard chemoradiotherapy as first-line treatment for limited-disease small cell lung cancer.
    Xu, Yaping
    Ni, Jian
    Ren, Shengxiang
    Xu, Xiaoling
    Hu, Min
    Xu, Qinghua
    Chen, Yun
    Zhu, Yaoyao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study
    Yi, Dong-Min
    Yang, Tao-Tao
    Chao, Shuai-Heng
    Li, Ya-Xin
    Zhou, Ying-Lei
    Zhang, Hai-Hui
    Lan, Ling
    Zhang, Yu-Wei
    Wang, Xue-Mei
    Zhang, Yan-Rui
    Li, Jian
    Ding, Song-Ze
    MEDICINE, 2019, 98 (06)
1